Sponsored by
This is interesting preclinical work showing that adding pemigatinib, a FGFR1-3 inhibitor, to tumor-treating fields (TTFields) reduced glioma stem cell (GSC) growth, survival, and clonogenicity in lab models. Adding radiation to the TTFields + pemigatinib combo also appeared to delay DNA damage repair, further enhancing the overall effect in some GSC lines. While this work is still early-stage, it could offer a new angle to overcoming TTFields therapy resistance.